TY - JOUR TI - Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation AU - Hua, Jingsheng AU - Zhang, Jian AU - Zhang, Xinyou AU - Wu, Xiaoxia AU - Zhou, Lili AU - Bao, Xiebing AU - Han, Yue AU - Miao, Miao AU - Li, Caixia AU - Fu, Chengcheng AU - Chen, Suning AU - Tang, Xiaowen AU - Wu, Depei AU - Qiu, Huiying T2 - Bone Marrow Transplantation AB - The efficacy and safety of donor-derived anti-CD19 CAR T cells vs DLI for the management of relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allo-hematopoietic stem cell transplantation (HSCT) remain unclear. Thirteen B-ALL patients with relapsed after allo-HSCT and thus were treated with donor-derived anti-CD19 CAR T-cell (study group). Fifteen B-ALL patients relapsed after allo-HSCT and thus were treated with DLI (DLI group). The rates of MRD-negative complete remission (61.5%) in the study group were significantly higher than those in the DLI group (13.3%) (p = 0.02). The complete remission duration in study group and DLI group were median 8.0 months (range, 3–25 months) and 4.4 months (range, 1–25 months; p = 0.026), respectively. The overall survival of patients in the study group was superior to that of the DLI group: 9.5 months (range,3–25 months) versus 5.5 months (range, 1–25 months; p = 0.030). One patient with grade 1 acute graft-versus-host disease (aGVHD) was identified in the study group. While five (33.3%) patients in the DLI group developed grades III–IV aGVHD. Three patients (23.07%) developed grade 3 or 4 cytokine release syndrome in the study group. This study suggested that donor-derived anti-CD19 CAR T-cell therapy is promising, safe, and potentially effective for relapsed B-ALL after allo-HSCT and may be superior to DLI. DA - 2020/11/24/ PY - 2020 DO - 10.1038/s41409-020-01140-6 DP - www.nature.com SP - 1 EP - 9 LA - en SN - 1476-5365 UR - https://www.nature.com/articles/s41409-020-01140-6 Y2 - 2020/11/27/20:19:58 ER -